MDT

86.18

-0.06%↓

121.18

+2.3%↑

VEEV

166.43

-0.89%↓

HQY

85.81

+0.96%↑

NEOG

9.48

+2.6%↑

MDT

86.18

-0.06%↓

121.18

+2.3%↑

VEEV

166.43

-0.89%↓

HQY

85.81

+0.96%↑

NEOG

9.48

+2.6%↑

MDT

86.18

-0.06%↓

121.18

+2.3%↑

VEEV

166.43

-0.89%↓

HQY

85.81

+0.96%↑

NEOG

9.48

+2.6%↑

MDT

86.18

-0.06%↓

121.18

+2.3%↑

VEEV

166.43

-0.89%↓

HQY

85.81

+0.96%↑

NEOG

9.48

+2.6%↑

MDT

86.18

-0.06%↓

121.18

+2.3%↑

VEEV

166.43

-0.89%↓

HQY

85.81

+0.96%↑

NEOG

9.48

+2.6%↑

Kodu・Aktsiate loetelu・MacroGenics Inc

MacroGenics Inc

Avatud

SektorTervishoid

3.48 1.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.36

Max

3.5300000000000002

Põhinäitajad
By Trading Economics
Sissetulek	-31M -14M
Müük	-32M 41M
Aktsiakasum	-0.22
Kasumimarginaal	-34.333
Töötajad	293
EBITDA	-37M -15M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+61.08% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	98M 221M
Eelmine avamishind	1.73
Eelmine sulgemishind	3.48

Uudiste sentiment

By Acuity

50%

162 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

1.47 / 1.64 Toetus ja vastupanu

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. apr 2026, 23:26 UTC

Kuumad aktsiad

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. apr 2026, 20:41 UTC

Suurimad hinnamuutused turgudel

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. apr 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. apr 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. apr 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. apr 2026, 22:08 UTC

Tulu

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. apr 2026, 22:06 UTC

Tulu

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

16. apr 2026, 20:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

16. apr 2026, 20:49 UTC

Tulu

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. apr 2026, 20:43 UTC

Tulu

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

16. apr 2026, 20:40 UTC

Market Talk

Tulu

Netflix Says Engagement Quality Hits New High -- Market Talk

16. apr 2026, 20:30 UTC

Kuumad aktsiad

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. apr 2026, 20:25 UTC

Tulu

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. apr 2026, 20:23 UTC

Tulu

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. apr 2026, 20:19 UTC

Tulu

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. apr 2026, 20:17 UTC

Tulu

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. apr 2026, 20:16 UTC

Tulu

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

61.08% tõus

12 kuu keskmine prognoos

Keskmine 5.67 USD 61.08%

Kõrge 9 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

162 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.